VivoSeq
Other

BPH

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

BPH is an early-stage landscape with 0 programs across 2 companies. The most active players are Kissei Pharmaceutical Co., Ltd., Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kissei Pharmaceutical Co., Ltd.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting1 · 14%
Not yet recruiting1 · 14%
Enrolling by invitation1 · 14%

Clinical Trials

Trial Activity

7 trials

Effects of TNF Blockade on Human BPH/LUTS
Recruiting·EEndeavor Health·Phase 2·NCT06062875·70 enrolled
Intermittent vs Daily Tamsulosin for LUTS/BPH
Not yet recruiting·MMansoura University·Phase 4·NCT07308002·288 enrolled
Patient Perspectives on the Trade-off Between Voiding Improvement and Sexual Dysfunction Following HoLEP
Enrolling by invitation·NNorthwestern University·N/A·NCT07660068·252 enrolled
Penthrox in Rezūm BPH
Completed·—·Phase 4·NCT04029012·10 enrolled
A Comparative Study of KSO-0400 in BPH Patients With LUTS
Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT01222650·400 enrolled
A Pumpkin Seed, Isoflavonoid and Cranberry Mix in LUTS/BPH
Completed·SSaint-Joseph University·N/A·NCT04146103·163 enrolled
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Completed·Sanofi logoSanofi·Phase 3·NCT00347061·148 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)